SML0413
FQI1
≥98% (HPLC)
别名:
8-(2-Ethoxyphenyl)-7,8-dihydro-1,3-Dioxolo[4,5-g]quinolin-6(5H)-one
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C18H17NO4
化学文摘社编号:
分子量:
311.33
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL (clear solution)
storage temp.
2-8°C
SMILES string
O=C1CC(C2=CC=CC=C2OCC)C3=CC4=C(OCO4)C=C3N1
InChI
1S/C18H17NO4/c1-2-21-15-6-4-3-5-11(15)12-8-18(20)19-14-9-17-16(7-13(12)14)22-10-23-17/h3-7,9,12H,2,8,10H2,1H3,(H,19,20)
InChI key
YKSYGLXHLSPWLB-UHFFFAOYSA-N
Biochem/physiol Actions
FQI1 inhibits the DNA-binding activity of LSF, a ubiquitous transcription factor that is up regulated in many hepatocellular carcinomas (HCC). FQI1 inhibits LSF-dependent luciferase reporter expression, blocks proliferation in cancer cell lines, and induces apoptosis in liver cancer cells but is not toxic to primary hepatocytes. FQI1 also inhibits tumor growth in a mouse HCC xenograft model.
FQI1 is an inhibitor of transcription factor LSF.
存储类别
11 - Combustible Solids
wgk
WGK 3
法规信息
新产品
此项目有
Jennifer L S Willoughby et al.
BMC cancer, 20(1), 552-552 (2020-06-17)
The oncogene LSF (encoded by TFCP2) has been proposed as a novel therapeutic target for multiple cancers. LSF overexpression in patient tumors correlates with poor prognosis in particular for both hepatocellular carcinoma and colorectal cancer. The limited treatment outcomes for
Seung Han Son et al.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), 10(33), e2305096-e2305096 (2023-10-17)
Despite advances in precision oncology, cancer remains a global public health issue. In this report, proof-of-principle evidence is presented that a cell-penetrable peptide (ACP52C) dissociates transcription factor CP2c complexes and induces apoptosis in most CP2c oncogene-addicted cancer cells through transcription
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML0413-25MG | 04061832633442 |
| SML0413-5MG | 04061832633459 |